National Cancer Institute
Dr. Jackson’s research interests center on evaluating the blood-brain barrier (BBB) of malignant gliomas. Her clinical and translational research focuses on transiently disrupting the BBB by pharmacologic means, in an effort to improve cytotoxic therapy to the central nervous system. She uses brain microdialysis, pharmacokinetic analysis, and preclinical models to study central nervous system (CNS) pharmacology. Dr. Jackson also leads collaborative preclinical and clinical studies focused on understanding BBB integrity in normal brain and malignant gliomas with the goal of developing novel treatment strategies for brain tumor patients.
National Cancer Institute, National Institute of Health
Therapeutic Targeting of the Blood-Brain Barrier in Pediatric Malignant Brain Tumors
The blood brain barrier (BBB) is known to limit the effectiveness of glioblastoma treatments. Using samples provided by the Children’s Brain Tumor Network, researchers seek to enhance understanding of the BBB environment and of therapeutics that can pass the BBB.
Diffuse Intrinsic Pontine Glioma
A presumptive diagnosis of DIPG based on classic imaging features, in the absence of a histologic diagnosis, has been routinely employed. Increasingly however, histologic confirmation is obtained for both entry into research studies and molecular characterization of the tumor. New approaches with